Background-Blood loss is a common complication of cardiac surgery. Evidence suggests that recombinant activated factor VII (rFVIIa) can decrease intractable bleeding in patients after cardiac surgery. Our objective was to investigate the safety and possible benefits of rFVIIa in patients who bleed after cardiac surgery. Methods and Results-In this phase II dose-escalation study, patients who had undergone cardiac surgery and were bleeding were randomized to receive placebo (nϭ68), 40 g/kg rFVIIa (nϭ35), or 80 g/kg rFVIIa (nϭ69). The primary end points were the number of patients suffering critical serious adverse events. Secondary end points included rates of reoperation, amount of blood loss, and transfusion of allogeneic blood. There were more critical serious adverse events in the rFVIIa groups. These differences did not reach statistical significance (placebo, 7%; 40 g/kg, 14%; Pϭ0.25; 80 g/kg, 12%; Pϭ0.43). After randomization, significantly fewer patients in the rFVIIa group underwent a reoperation as a result of bleeding (Pϭ0.03) or required allogeneic transfusions (Pϭ0.01). Conclusions-On the basis of this preliminary evidence, rFVIIa may be beneficial for treating bleeding after cardiac surgery, but caution should be applied and further clinical trials are required because there is an increase in the number of critical serious adverse events, including stroke, in those patients randomized to receive rFVIIa. (Circulation. 2009; 120:21-27.)
B
leeding after cardiac surgery is a serious complication, and excessive blood loss frequently necessitates transfusion of allogeneic blood, blood products, and surgical reexploration. Five percent to 7% of patients lose Ͼ2 L blood within the first 24 hours after surgery, 1 and up to 5% require reoperation for bleeding. 2 Both transfusion and re-exploration are associated with prolonged intensive care and hospital stays and reduced survival rates. 3 
Clinical Perspective on p 27
Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) is currently approved for the treatment of bleeding episodes and the prevention of bleeding in connection with surgical/invasive procedures in patients with hemophilia and inhibitors to coagulation factors VIII or IX, FVII deficiency, and acquired hemophilia. The mode of action of rFVIIa has been described and is localized predominantly to the site of vessel injury. 4, 5 Numerous reports have indicated a reduction in bleeding and transfusion requirements in patients given rFVIIa in the setting of severe uncontrolled hemorrhage outside hemophilia and other bleeding disorders despite the potential for thrombotic complications. 6 -16 For patients bleeding after cardiac surgery, the risk, potential benefits, and optimal dose of rFVIIa have not been carefully assessed in a randomized, placebo-controlled trial.
Our objective was therefore to investigate the safety and possible benefits of different doses of rFVIIa in patients bleeding after cardiac surgery requiring cardiopulmonary bypass (CPB) in whom conventional transfusion therapy was indicated. We hypothesized that the use of rFVIIa to reduce bleeding in the postoperative setting after cardiac surgery requiring CPB was safe.
Methods
This phase II dose-escalation study was conducted at 30 sites in 13 countries between August 2004 and November 2007. The trial was approved by national, local, and institutional ethics committees and/or review boards as applicable. Written informed consent was obtained before surgery from each patient who met the inclusion criteria (Table I of 
Patients
Patients eligible for randomization had undergone cardiac surgery requiring CPB and had been admitted to a postoperative care environment (eg, intensive care unit) for at least 30 minutes (stabilization period). Patients were randomized on reaching a prespecified bleeding rate (Table I of 
Randomization, Study Monitoring, and Masking
A randomized, double-blind, placebo-controlled trial design was used for each of the individual dose tiers (cohorts). Patients meeting the inclusion criteria were randomized to rFVIIa or placebo. Initially, patients were to be allocated sequentially to 3 cohorts of escalating rFVIIa doses (40, 80, and 160 g/kg rFVIIa). Cohort 1 comprised 70 patients equally allocated to 40 g/kg rFVIIa or placebo. Cohort 2 comprised 51 patients randomized 2:1 (80 g/kg rFVIIa:placebo). Safety and efficacy data were evaluated by a Novo Nordisk Safety Committee and an independent external Data Monitoring Committee at the end of cohort 1, then after every 10 patients randomized in cohort 2a, and every month in cohort 2b. The Data Monitoring Committee had access to all data at the end of each cohort to evaluate the incidence of critical serious adverse events (cSAEs) and advised the sponsor and the Steering Committee if the trial should continue. After completion of the original cohort 2 (cohort 2a), the Data Monitoring Committee recommended duplication of cohort 2 to clarify concerns raised by the data available to the committee. The protocol was amended by including an additional cohort (cohort 2b) with 51 patients randomized 2:1 (80 g/kg rFVIIa:placebo). At the recommendation of the Steering Committee (masked to treatment allocations), the study was terminated before initiation of cohort 3 (160 g/kg rFVIIa versus placebo). The committee's advice was based on the data within the expanding cardiac literature in which doses of rFVIIa were in the range of 60 g/kg. 6, 9, 10, 15 Patients were randomized through an interactive voice response system and were always assigned to the lowest available randomization number. After randomization, freeze-dried powdered (4.8 mg) rFVIIa or placebo was reconstituted with 8.5 mL sterile water and administered as a bolus injection. To maintain masking within each dose level, an equal volume per body weight of trial product was administered to all patients regardless of treatment group. Physical appearances of the placebo and rFVIIa, either in the freeze-dried form or on reconstitution, were identical. Masking of treatment allocations was maintained until all patient data had been entered and the database was locked.
Transfusion Protocol
No changes to standard practices (eg, anesthesia, surgical practice, CPB, or intensive care) were made until patients reached the prespecified rate of bleeding in a postoperative environment that allowed randomization. At this time, all transfusions except allogeneic red blood cells were discontinued. The transfusion protocol was applied from randomization to day 5 but suspended during reoperations. This protocol is presented as Figure I of the online-only Data Supplement.
End-Point Definitions
The primary end point for the study was the incidence of cSAEs from trial drug administration to day 30. The cSAEs as defined for this trial were death, acute myocardial infarction (ECG evidence of Ն1 new Q waves, left bundle-branch block, or new pathological R waves; troponin T Ͼ3.4 g/L at 48 hours after surgery; or an increase in creatine kinase-MB Ͼ30 g/L at 2 consecutive time points Ͼ24 hours after surgery, plus a clinical picture of hemodynamic instability that gives rise to the suspicion of myocardial infarction or graft occlusion), cerebral infarction (new focal neurological deficit, either transient but present Ͼ24 hours or permanent), clinically symptomatic pulmonary embolus (clinical signs or suspicion of pulmonary embolus further diagnosed by V/Q scan or postmortem examination; clinical examination is not sufficient for diagnosis), and other clinically symptomatic thrombotic events (signs or suspicion of clinically significant thromboembolic event Figure 1 . Numbers of patients who consented, were randomized, and completed the study. Of the 7 patients who were randomized but did not receive study drug, 3 were allocated to the placebo group, 3 to the 40 g/kg group, and 1 to the 80 g/kg group. In 4 of the 7 patients, the interactive voice response system (IVRS) was called prematurely and was the most common reason for lack of study drug administration. For the remaining 3 patients, there was 1 case each of IVRS called despite not meeting inclusion criterion for bleeding rate, IVRS called but the patient had to go back for reoperation, and IVRS not working.
confirmed by positive finding in a follow-up investigation such as a lower-limb venogram or duplex Doppler studies).
Secondary end points evaluated efficacy and included the rates of reoperation within 30 days after rebleeding, transfusion of allogeneic blood and blood products within 5 days after trial drug administration, and drainage volumes from cardiothoracic cavity within 4 hours, 24 hours, and 5 days after trial drug administration.
Statistical Analyses
The data presented in this study are for the safety population (defined as all patients randomized who received either rFVIIa or placebo treatment). Sample size was based on the probability that uneven distribution of cSAEs between placebo and rFVIIa treatment groups would be minimized. That is, sample size was chosen to have Յ20% risk of seeing Ն14 (of 35) on active versus Յ7 (of 35) on placebo or Յ7 on active versus Ն14 on placebo in cohort 1 and Յ16.7% risk of Ն13 (of 34) on active versus Յ2 (of 17) on placebo or Յ7 on active versus Ն8 on placebo in cohorts 2a, 2b, and 3, all assuming no differences and 21 events in cohort 1 and 15 events in cohorts 2a, 2b, and 3. Additionally, the sample size was chosen to give adequate power to detect a 35% reduction in the need for any allogeneic transfusions. The power for the efficacy evaluation is based on a comparison of (all) placebo patients with the highest dose of rFVIIa (ie, cohort 3). This simple comparison between 2 groups (86 on placebo versus 34 on rFVIIa) then has 80% power assuming 80% transfusion rate on placebo and a 35% relative reduction [to 52%ϭ80%ϫ(100%Ϫ35%)].
All analyses presented, including covariates, were prespecified in the statistical analysis plan unless stated otherwise (eg, posthoc analysis). The frequency of cSAEs (primary end point) was analyzed by logistic regression adjusted for the prespecified variables of prior cardiac surgery, use of antifibrinolytic medication, and treatment.
Reoperation for bleeding was analyzed with 2 tests. Continuous efficacy end points (drainage rates, drainage volumes, transfusion volumes) were analyzed by ANCOVA with adjustment for the prespecified variables of prior cardiac surgery, CPB time, use of antifibrinolytic medication, country, and treatment. Analyses of drainage volumes and rates also were adjusted for predosing drainage rate or predosing transfusions volume as appropriate. Data were transformed to ranks because they were not normally distributed and were substantially skewed. This analysis was considered a nonparametric test adjusted for relevant covariates. Estimates are presented as medians.
Categorical efficacy outcomes (percentage of subjects having transfusion, combined and by type) were analyzed by logistic regression adjusted for prespecified variables of prior cardiac surgery, use of antifibrinolytic medication, and treatment.
The authors designed the trial protocol (Appendix A in the online-only Data Supplement), directed the statistical analysis plan, and wrote the manuscript. The sponsor was responsible for trial operations and the statistical analyses. The principal investigator (R.G.) assumes full responsibility for the veracity and completeness of the reported data.
Results

Baseline Characteristics
A total of 2619 patients gave informed consent before surgery; of these, 179 patients met the postoperative inclusion criteria and were randomized, and 172 patients were dosed (Figure 1) . Overall, 158 patients (92%) survived the trial and 14 patients (8%) died. The distribution of age, gender, body surface area, types of surgery, rates of previous cardiac surgery, and surgery details are provided in Table 1 . There were no statistically significant differences between treatment groups. Randomization and trial drug dosing occurred on average 2.8 hours after admission to the postoperative care unit.
Safety End Points
There were more cSAEs in the rFVIIa treatment group than in the placebo treatment group (Table 2) ; this difference did not reach statistical significance. Because only 1 myocardial infarction was identified in the study, an external adjudication committee was asked to evaluate all patients with elevated cardiac biomarkers. The findings of the committee did not alter the original results reported (Table II of the online-only Data Supplement). The only myocardial infarction in the study (placebo group) was originally reported as a nonserious adverse event. This was changed to a cSAE by the sponsor to comply with the trial protocol. It does not alter the statistical findings in this trial.
The statistical analysis plan specified that analyses of cSAEs should be adjusted for treatment, country or center, prior cardiac operation, and administration of antifibrinolytics. Because there were only 18 events, this could not occur. There were a total of 14 deaths (placebo, 4 deaths [6%]; combined rFVIIa dose groups, 10 deaths [10%]) in this study (Table 2) . A representation of the time to cSAE and/or death for each patient is provided in Figure 2 .
Efficacy End Points
After trial drug administration, significantly more patients in the placebo group underwent a reoperation for bleeding than in either of the rFVIIa treatment groups (placebo, 25%; 40 g/kg rFVIIa, 14% [Pϭ0.21]; 80 g/kg rFVIIa, 12% [Pϭ0.04]; Figure 3A) .
After dosing, patients in the rFVIIa treatment groups received significantly less allogeneic blood transfusion volumes than placebo-treated patients (placebo, 825 mL [25% to 75% interquartile range (IQR), 326.5 to 1893 mL]; 40 g/kg rFVIIa, 640 mL [25% to 75% IQR, 0 to 1920 mL], Pϭ0.047; 80 g/kg rFVIIa, 500 mL [25% to 75% IQR, 0 to 1750 mL], Pϭ0.042) respectively. The proportion of patients avoiding transfusions was significantly higher in both rFVIIa treatment groups compared with placebo treatment ( Figure 3B ).
Four hours after randomization and drug administration, the median drainage rate in the 80 g/kg rFVIIa group was significantly slower (24 mL/h; 25% to 75% IQR, 13.3 to 32.0 mL/h; Pϭ0.018) than in the placebo (51 mL/h; 25% to 75% IQR, 21.3 to 82.7 mL/h) and 40 g/kg rFVIIa (35 mL/h; 25% to 75% IQR, 26.7 to 85.3 mL/h; Pϭ0.763) groups. Consequently, there was an Ϸ50% reduction in the drainage volume within 4 hours after treatment with 80 g/kg rFVIIa (PϽ0.001) compared with placebo ( Figure IIA of the onlineonly Data Supplement). Evaluation of the cumulative drainage volumes at 24 hours and 5 days after dose indicated that this difference was maintained for the 80 g/kg rFVIIa treatment group compared with placebo treatment ( Figure IIB and IIC of the online-only Data Supplement). No such difference was observed between placebo and 40 g/kg rFVIIa.
Discussion
In this trial, we observed a numerical increase in cSAEs in patients randomized to rFVIIa compared with placebo. However, this difference was not statistically significant. In our results, the unadjusted and adjusted log odds ratios for the incidence of adverse events are similar to placebo. Our results show that patients receiving rFVIIa had significantly fewer Cerebral infarction, n (%) 0 2 (6) 2 (3)
Myocardial infarction, n (%) 1 (2) 0 0
Pulmonary embolism, n 0 0 0
Patients with cSAEs, n (%) 5 (7) 5 (14) 8 (12) 13 ( Other thrombotic events (TEs) included gut infarction (1 event each in the 40 and 80 g/kg groups) and 1 superficial venous thrombosis (80 g/kg). Columns are not additive because some patients may have had multiple cSAEs. Probability values were adjusted for prior cardiac surgery and antifibrinolytics and compared with placebo. Percentages are based on the number of patients in each treatment group. There were more cSAEs in the rFVIIa treatment group than in the placebo treatment group; this difference did not reach statistical significance.
*One patient in the 80 g/kg group died outside the 30-day study window (day 32).
reoperations and significantly less transfusion of allogeneic blood and blood products after randomization.
Safety of rFVIIa
Bleeding after cardiac surgery may lead to transfusion of allogeneic blood and blood products and/or reoperation.
Transfusion of blood at the time of cardiac surgery is associated with a decreased long-term survival. [17] [18] [19] [20] [21] Receipt of 5 U allogeneic red blood cells is associated with an 8-fold increase in the chance of death. 22 Moreover, if bleeding does not stop, the patient will require reoperation, which may lead to a prolonged intensive care and hospital stay, increasing the risk of wound infections and marked reductions in the 3-year survival rates. 3 Recent reviews have identified 415 patients who received rFVIIa for life-threatening bleeding after cardiac surgery. 15, 23 In these reviews, only a few suffered thromboembolic complications after the administration of rFVIIa, but the tendency for clinicians to report only those successful cases cannot be excluded. On the other hand, a review of the Food and Drug Administration's adverse event reporting system suggests that 1 in 50 patients (from many medical disciplines) receiving rFVIIa for an unapproved indication developed a thromboembolic complication, with 1 in 200 patients dying. 11 In cardiac surgery, mortality and complication rates of patients who have failed to respond to standard transfusion therapy and then received rFVIIa are in range of 19% to 40%. 10, 14, 24, 25 The lack of control patients in most of these case series makes it difficult to determine whether the reported adverse events are related to the administration of rFVIIa or the critical unstable condition of patients when they received rFVIIa. When rFVIIa was used on a compassionate basis to reduce uncontrolled bleeding in 51 patients after cardiac surgery, propensity matching techniques to adjust for baseline risks demonstrated that the rates of cSAEs were equivalent. 26 In a group of patients with very high risk of stroke, a matched analysis of patients receiving rFVIIa after major ascending and aortic arch reconstructive surgery suggested that the stroke rates were equal. 27 Although our study is underpowered to make a definitive statement about cSAEs, in this study, we see a numerical increase in cSAEs in rFVIIa-treated patients. This finding is consistent with the absolute rate of cSAEs reported in observational data. This is the first randomized trial attempting to examine the risks of rFVIIa in patients bleeding enough to justify the administration of blood products after cardiac surgery. Our results show a numerical but statistically insignificant increase in cSAEs compared with placebo. The findings suggest the need for a cautious approach and additional trials.
Efficacy of rFVIIa
There is a clinical sentiment that rFVIIa decreases bleeding. 9, 10, 13, 15, 23, 25, 28 This is illustrated by an increase in the off-label use of rFVIIa from 300 doses in 1999 to 4500 doses in 2004 11 and numerous case reports and case series reporting its efficacy in reducing bleeding and transfusion requirements. Recombinant FVIIa also has been shown to significantly reduce transfusion in a small randomized pilot study of patients undergoing major cardiac reconstructive surgery. 29 The results of this randomized controlled trial support these observations, and for the first time, a hemostatic agent has the possibility of being an effective alternative to allogeneic transfusion in cardiac surgery patients with uncontrolled postoperative bleeding. 
Limitations
The major limitation of this study is its small sample size. Consequently, some of the patients who received rFVIIa were older, were on CPB longer, and received more transfusions before randomization. These factors are all recognized as being strong predictors of cSAEs and mortality and may partially account for the numerical difference observed between groups. Other factors that may have contributed to group imbalance were the time taken to complete the study (4 years) and the 2:1 (rFVIIa: placebo) randomization ratio in cohorts 2a and 2b. Although more patients were exposed to rFVIIa in the later phase, all placebo patients were counted as 1 cohort. It is, however, a pragmatic study in that rFVIIa administration mirrored clinical practice, although at a lower rate of bleeding than salvage compassionate use.
Conclusions
The results of this trial should be interpreted with caution, and we cannot say at this time that using rFVIIa is safe in this population. The study is underpowered, and our findings could be the result of a type II error. The numerical increase in the number of cSAEs with rFVIIa could be a true finding or the result of chance. The possible efficacy of rFVIIa can be interpreted and applied only within this population. We conclude that using rFVIIa in patients bleeding after cardiac surgery may be beneficial, but caution should be applied and further clinical trials are required. Percentages are based on the number of patients randomized and dosed (placebo, nϭ68 patients; 40 g/kg rFVIIa, nϭ35 patients; 80 g/kg rFVIIa, nϭ69 patients). P values were determined in comparison to placebo treatment values with 2 tests. B, Percentage of patients avoiding transfusions after administration of trial drug. Percentages are based on the number of patients randomized and dosed (placebo, nϭ68 patients; 40 g/kg rFVIIa, nϭ35 patients; 80 g/kg rFVIIa, nϭ69 patients).
